DBV Technologies S.A.

NASDAQ:DBVT

Biotechnology

Healthcare
$9.68 -0.95%

-$0.16 today

Market cap
$231.56M
Beta
-0.22
P/E (TTM)
-8.3
EPS (TTM)
-$0.39
52W Low $8.50High $26.19

Volume 0.14M

Average 0.24M

DBVT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

DBV Technologies S.A.NASDAQ: DBVT

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $88.9M rose 197455.6% year over year, ahead of the +52499.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 44.1% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +197455.6% holds above the trailing-twelve-month pace of +52499.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$88.9M-44.1% QoQ
Last fiscal yearDec 2025
$276.18M+46949.7% YoY
LTMMar 2026
$365.04M+52499.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+197455.6%——
1 year+46949.7%——
3-year CAGR+12.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
276.18M USD
Year-over-year change
+46949.7%
4-year CAGR
+463.5%

Financing Cash Flow vs competitors

How DBVT compares with its peers on the latest reported figures

  • DBVT's LTM Mar 2026 financing cash flow of $365.04M is the 2nd largest of the 11 companies compared; the peer median is $154.48M.
  • Its year-over-year change of +52499.0% is the 3rd highest of 10, against a peer median of +136.8%.
  • Over three fiscal years its annual growth of +12.5% compares with a peer median of +53.9%.
DBVT Competitors Peer median
Financing Cash Flow for DBVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$396.39M —+136.2%—
DBVTDBV Technologies S.A.LTM Mar 2026$365.04M +52499.0%+12.5%—
ALTAltimmune, Inc.LTM Mar 2026$251.49M +466.1%+53.9%698594.4%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$219.24M +164739.1%+946.8%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$173.2M +64727.2%-4.7%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$165.89M +1517.0%+11.1%—
ENGNenGene Holdings Inc.LTM Apr 2026$143.06M +136.8%-62.1%—
ANNXAnnexon, Inc.LTM Mar 2026$141.69M +10.0%-4.0%—
KRROKorro Bio, Inc.LTM Mar 2026$88.73M +27.9%+236.4%2309.3%
CLLSCellectis S.A.LTM Mar 2026$17.39M -123.8%—25.5%
AMRNAmarin Corporation plcLTM Mar 2026$2.59M +127.8%+75.3%1.2%
Peer median (excluding DBVT) $154.48M+136.8%+53.9%1167.4%

Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.81M)(96.27M)(72.73M)(113.92M)(146.95M)
Depreciation & Amortization8.38M13.16M(14M)(925K)3.19M
Deferred Income Tax184K0000
Stock-Based Compensation3.12M5.03M6.02M4.62M5.39M
Change in Working Capital(22.77M)22.32M953K5.75M1.34M
Accounts Receivables2.15M0000
Inventory(16.18M)000(16.11M)
Accounts Payables(7.56M)3.46M8.42M272K15.83M
Other Working Capital(1.19M)18.86M(7.47M)5.48M1.62M
Other Non-Cash Items656K66K99K(3K)15.84M
Operating Cash Flow(108.24M)(55.7M)(79.65M)(104.47M)(121.18M)
Capital Expenditures(918K)(754K)(677K)(2.34M)(533.64K)
Acquisitions (Net)511.01K7.61K000
Purchases of Investments(119K)(123K)(285K)00
Sales of Investments(511.01K)770K154K00
Other Investing Activities604K(611)(131K)1.58M(829.34K)
Investing Cash Flow(433K)(100K)(808K)(757K)(1.37M)
Debt Repayment(582.92K)(474K)000
Common Stock Issued978K194.59M6.92M634K277.04M
Common Stock Repurchased00(154K)(47K)0
Dividends Paid00000
Other Financing Activities(121.08K)(20K)00(854.56K)
Financing Cash Flow274K194.1M6.77M587K276.18M
Effect of Forex Changes(10.65M)(6.5M)5.87M(4.27M)8.08M
Net Change in Cash(119.05M)131.9M(67.83M)(108.91M)161.71M
Free Cash Flow(109.16M)(56.45M)(80.33M)(106.82M)(121.18M)

DBV Technologies S.A.

NASDAQ:DBVT

Intrinsic Alpha fair value

Locked

Current Price

$9.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.